Investors
CSL is a global biotech leader. Our dedicated management and employees are driven to fulfill our promise to patients to deliver life-saving and life-improving therapies that help many thousands of people live full lives.
Investor InformationSearch Results
1021 results found-
The value at vesting has been determined by multiplying the number of vested units by the closing share price on the date of vesting or in the case of the awards to vest on 1 September 2025, the closing share price at 30 June 2025.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2025.pdf -
Approval is also required before which could affect CSL's share price.
https://www.csl.com/-/media/shared/documents/one-csl/code-of-conduct/code-of-conduct-english.pdf -
Total LTI Reward LTI Growth in Received (valued Value (due to 2023 Total Fixed 2023 STI LTI Vested in Total Reward at grant date) share price Executive Received US$2 US$3 2023 US$4 Reward US$ US$5 growth) US$6 Period Earned 2023 2023 2019 - 2023 2019 - 2023 2019 - 2023 2019 - 2023 P McKenzie 1,340,311 1,376,890 1,634,350 4,351,551 1,446,967 187,383 J Linton 1,044,351 946,395 1,003,581 2,994,327 901,287 102,294 Former Executive KMP P Perreault7 1,354,165 1,537,182 3,148,999 6,040,346 2,806,440 342,559
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
calculated based on independent and valuation Performance Options - Increase the proportion of remuneration linked to long term share price growth - Share price appreciation from grant and consistent achievement of individual performance metrics.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
19 The face value is calculated using a share price of A$227.31 being the share price on the date of grant - 1 September 2018.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
39 The value at grant date has been determined by the share price at the close of business on the grant date of 22 August 2019 being A$238.86 and for C Hewson the share price at the close of business on 20 February of A$338.68 multiplied by the number of Rights granted during 2020.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
33 The face value is calculated using a share price of A$133.96 being the share price on the date of grant - 1 October 2017.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
21 The number of Options is calculated based on an assessment of the fair market value of the instruments in accordance with the accounting 19 The face value is calculated using a share price of A$107.00 being the share price on the date of grant.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia - Sep 24, 2024
Zeria expects to begin to market Veltassa ® following National Health Insurance price listing.
https://newsroom.csl.com/2024-09-24-Veltassa-R-patiromer-approved-in-Japan-for-the-treatment-of-adults-with-hyperkalemia -
the appropriate transfer price for transactions between International CSL has a low appetite for tax risk and Related Parties.
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2024-25.pdf